These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2289217)

  • 41. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
    Farnier M; Bonnefous F; Debbas N; Irvine A
    Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
    Hunninghake DB; Peters JR
    Am J Med; 1987 Nov; 83(5B):44-9. PubMed ID: 3318453
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F; Szczechowska E
    Z Gesamte Inn Med; 1981 Jul; 36(13):454-7. PubMed ID: 7025475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
    Neuman MP; Kurlat MI; Neuman J
    Curr Med Res Opin; 1983; 8(5):358-67. PubMed ID: 6839800
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of a new calcium channel blocker, TA 3090, on serum lipoprotein levels in mild to moderate essential hypertension.
    Sasaki J; Ideishi M; Saku K; Arakawa K; Tominaga K; Saeki Y; Otake N; Kawasaki K; Shirai K; Sumida I
    Clin Ther; 1990; 12(4):327-34. PubMed ID: 2224947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
    Schwandt P; Weisweiler P; Drosner M; Janetschek P
    Atherosclerosis; 1982 Apr; 42(2-3):245-9. PubMed ID: 7073803
    [No Abstract]   [Full Text] [Related]  

  • 48. [Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life].
    Reuter W
    Z Alternsforsch; 1982; 37(6):409-16. PubMed ID: 7164480
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Application of the immunoenzyme technic in double determination of antibodies for the study of hyperlipoproteinemia].
    Kandoussi A; Cachera C; Reade R; Tacquet A; Fruchart JC
    Ann Biol Clin (Paris); 1990; 48(6):365-8. PubMed ID: 2221495
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Multicenter study of the efficacy and tolerance of gemfibrozil and fenofibrate in the treatment of primary hyperlipoproteinemia].
    Manojlović D; Lepsanović L; Micić D; Sumarac M; Kendereski L; Popović V; Mićić J
    Srp Arh Celok Lek; 1991; 119(1-2):22-5. PubMed ID: 1788614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia.
    Packard CJ; Stewart JM; Third JL; Morgan HG; Lawrie TD; Shepherd J
    Biochim Biophys Acta; 1980 Apr; 618(1):53-62. PubMed ID: 6990991
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia.
    Olsson AG; Lang PD; Vollmar J
    Atherosclerosis; 1985 May; 55(2):195-203. PubMed ID: 4004990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment of hyperlipidemia type II with soybeans].
    Noseda G; Fragiacomo C; Bosia C; Ramelli F; Sirtori CR
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1852-3. PubMed ID: 231304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.
    Weintraub MS; Eisenberg S; Breslow JL
    J Clin Invest; 1987 Apr; 79(4):1110-9. PubMed ID: 3470306
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Very low density lipoprotein (VLDL) pattern in primary hyperlipoproteinaemia type IIb and type IV.
    Kłosiewicz-Latoszek L; Naruszewicz M; Cybulska B; Szostak WB; Chotkowska E
    Mater Med Pol; 1979; 11(3):230-4. PubMed ID: 232894
    [No Abstract]   [Full Text] [Related]  

  • 56. [Evaluation of the efficiency of gemfibrozil in treating hyperlipidemia type IIb and IV].
    Polakowska M; Broda G; Rywik S; Piotrowski W; Bednarska M; Kuźmińska A; Pytlak A; Chotkowska E
    Pol Arch Med Wewn; 1994 Jan; 91(1):9-18. PubMed ID: 8190659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Modification of pathologic fatty acid patterns in old age by combined clofibrinic and nicotinic acid treatment].
    Reuter W
    Z Alternsforsch; 1983; 38(5):383-8. PubMed ID: 6659567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia.
    Knopp RH; Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Goldberg AC; Grundy SM; Lasser NL; Mellies MJ; Palmer RH
    Am J Med; 1987 Nov; 83(5B):50-9. PubMed ID: 3318454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
    Rouffy J; Chanu B; Bakir R; Djian F; Goy-Loeper J
    Atherosclerosis; 1985 Mar; 54(3):273-81. PubMed ID: 3994783
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
    Sirtori M; Montanari G; Gianfranceschi G; Malacrida MG; Battistin P; Morazzoni G; Tremoli E; Colli S; Maderna P; Sirtori CR
    Atherosclerosis; 1983 Nov; 49(2):149-61. PubMed ID: 6365105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.